louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01932398: A Study on the Inter-Hemispheric Alpha Ratio in Kids With ADHD (SHARK)
Official title: Posterior Alpha Oscillations as an Index for the Attentional Bias in Children With Attentional Deficit Hyperactivity Disorder
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: ADHD
Keywords: Alpha
Lateralization
Attention
ADHD
Oscillation
Lead sponsor: Radboud University Medical Center
Sponsor class: OTHER
First posted: 2013-08-30
Enrollment: 60
Sex: ALL
Minimum age (years): 84
Maximum age (years): 95
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: ADHD vs no ADHD

Brief summary: Investigate the hypothesis that children with ADHD have difficulty with the allocation of visio-spatial attention related to an inability to control posterior alpha brain oscillations. A paradigm will be used in which the aim is to address covert attention as similar recent studies did in adults with ADHD.


Eligibility criteria: Inclusion Criteria:

For both groups

* Age between 7 and 10 years of age.
* Estimated IQ above 80.
* Psychopharmaca- naïve or -free.

For the ADHD-group - A diagnosis of ADHD, classified by the DSM-IV.

Exclusion Criteria:

* (Co-morbid) psychiatric disorder (major depression, bipolar disorder, psychotic disorder, chronically motor tic disorder or Gilles de la Tourette, Conduct disorder, autism spectrum disorder, eating disorder, anxiety disorder).
* Neurological disorders (e.g. epilepsy) currently or in the past.
* Cardiovascular disease currently or in the past.
* Serious motor or perceptual handicap.

For the no ADHD-group

- No diagnosis of ADHD, classified by the DSM-IV.

Primary outcomes:
measure: Modualtion of alpha power
timeFrame: Once for half an hour
Secondary outcomes:
measure: Response time on covert attention task
timeFrame: Once for half an hour
measure: Standard deviation of response time on covert attention task
timeFrame: Once for half an hour
measure: Correct responses on covert attention task
timeFrame: Once for half an hour
measure: Mean deviation from middle on line bisection task
timeFrame: Once in about 5 minutes
measure: Inattention score on the ADHD-RS-IV
timeFrame: Once in about 10 minutes
measure: Hyperactivity/impulsivity score on the ADHD-RS-IV
timeFrame: Once in about 10 minutes
Other outcomes:
measure: FSIQ estimation
timeFrame: Once in about 20 minutes
Locations:
city: Nijmegen
country: Netherlands
facility: Donders Institute for Brain, Cognition and Behavior, Centre for Cognitive Neuroimaging
state: Gelderland
Study officials:
affiliation: Donders Institute for Brain, Cognition and Behavior - Centre for Cognitive Neuroimaging
name: Ole Jensen, Prof
role: PRINCIPAL_INVESTIGATOR
affiliation: Radboud University, Medical Centre - Donders Institute for Brain, Cognition and Behavior, Department of Cognitive Neuroscience
name: Jan K Buitelaar, Prof
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02252198: Evaluation of Non-Inferiority of Two Fast Follower Nucleic Acid Amplification Tests
Official title: Evaluation of Non-Inferiority of Two Fast Follower Nucleic Acid Amplification Tests for the Diagnosis of Pulmonary Tuberculosis in Comparison to Geneexpert MTB/RIF
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Tuberculosis
Lead sponsor: Johns Hopkins University
Sponsor class: OTHER
Collaborators: name: Boston Medical Center
First posted: 2014-09-30
Enrollment: 504
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adults with clinical suspicion of pulmonary TB.

Brief summary: Assess sensitivity and specificity of two nucleic acid amplification tests, namely Epistem Genedrive® and MolbioTruenat™ in raw sputum compared to the WHO-endorsed GeneXpert® MTB/RIF assay using a gold standard of four cultures

Detailed description: * Estimate the accuracy of the Epistem Genedrive® and MolbioTruenat™ in raw sputum and in sputum pellets.
* Assess the operational feasibility of Epistem Genedrive® and MolbioTruenat™
* Determine and compare costs between the Epistem Genedrive®, MolbioTruenat™, and Xpert MTB/RIF tests

Eligibility criteria: Inclusion Criteria:

* • Clinical suspicion of pulmonary TB (including cough ≥2 weeks and at least 1 other symptom typical of TB);

  * Age 18 years or above;
  * Willingness to have a study follow-up visit, if necessary, approximately two months after enrollment
  * Willingness to provide 3 sputum specimens at enrollment
  * Provision of informed consent.

Exclusion Criteria:

* • Receipt of ≥48 cumulative hours OR three or more doses of anti-TB treatment (defined as combination anti-TB therapy intended to treat active TB) within 60 days prior to completion of sputum collection;

  * Inability to provide informed consent (e.g. mentally impaired)
  * Enrolled individuals who do not provide a first sputum sample of ≥ 2ml and a second and third sputum sample of ≥ 1ml each will be classified as early exclusions.

Primary outcomes:
measure: Non-inferiority of tests
timeFrame: 4 months
measure: Sensitivity and specificity of Epistem Genedrive® MTB iD
timeFrame: 4 months
measure: Sensitivity and specificity of MolBio Truenat™ TB Assay
timeFrame: 4 months
Secondary outcomes:
measure: Failure rate for the Epistem Genedrive® system assay and for the MolBio Truenat™ assay
timeFrame: 10 months
measure: Training needs for each assay
timeFrame: 10 months
measure: Operational feasibility
timeFrame: 10 months
measure: Cost-comparison between assays
timeFrame: 10 months
Other outcomes:
Locations:
city: Baltimore
country: United States
facility: Johns Hopkins University
state: Maryland
Study officials:
References:
Clinical trial NCT01788098: Genetics and Mechanisms of Rheumatoid Arthritis
Official title: Rheumatoid Arthritis Susceptibility Genes in Austrian and Slovak Population
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Rheumatoid Arthritis
Leukocytes, Mononuclear
Genetic Association Studies
Lead sponsor: Slovak Academy of Sciences
Sponsor class: OTHER_GOV
First posted: 2013-02-11
Enrollment: 790
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with rheumatoid arthritis and healthy controls from Slovakia and Austria

Brief summary: The study is aimed at revealing genetic background in rheumatoid arthritis (RA). For that purpose samples of DNA will be collected from 500 RA patients and similar number of controls from whole Slovakia. Variations in several genes associated with RA will be evaluated. The second aim is to assess functional changes in immune cells from selected patients and their evaluation together with genetic background. The project has observational character without any intention to change the treatment of RA patients.


Eligibility criteria: Inclusion Criteria:

* rheumatoid arthritis or healthy

Exclusion Criteria:

Primary outcomes:
measure: Genetic association
timeFrame: 1 day
Secondary outcomes:
measure: Peripheral blood mononuclear cells reactivity
timeFrame: 1 day
Other outcomes:
Locations:
city: Bratislava
country: Slovakia
facility: Slovak Academy of Sciences, Center for Molecular Medicine
Study officials:
affiliation: Slovak Academy of Sciences, Center for Molecular Medicine
name: Richard Imrich
role: STUDY_CHAIR
References:
Clinical trial NCT06530498: Diagnostics of Clinical Hyperandrogenism
Official title: Diagnostics of Clinical Hyperandrogenism Using the Modified Ferriman-Gallwey Scale and the Ludwig Scale in Women With Normogonadotropic Anovulation
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Anovulation
PCOS
Keywords: Hirsutism
Normogonadotropic Anovulation
PCOS
androgenetic alopecia
Lead sponsor: Jagiellonian University
Sponsor class: OTHER
First posted: 2024-07-31
Enrollment: 300
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Women diagnosed and treated at the University Hospital in Krakow due to normogonadotropic anovulation

Brief summary: The optimal cut-off value for diagnosing hirsutism in the modified Ferriman-Gallwey (mFG) point scale in the Polish population is not known. The correlation of mFG with the severity of androgenetic alopecia in the Ludwig scale (LS) is not known.

The aim of the study is to determine the cut-off point for the diagnosis of hirsutism and to assess the correlation of the mFG scale score with the LS of androgenetic alopecia severity.

Detailed description: The aim of the study is to:

* determine the cut-off point on the mFG scale, indicating hirsutism and to determine the correlation of the severity of androgenetic alopecia on the Ludwig scale with the mFG value in the population of women diagnosed and treated at the University Hospital in Krakow due to anovulation.
* to determine the severity of hirsutism and the severity of androgenetic alopecia in individual PCOS phenotypes.

Inclusion criteria are as follows: i) oligoovulation, i.e. menstrual cycles every \<21 days or \>35 days, ii) age 18-45 years, iii) diagnosis of PCOS.

Exclusion criteria: none.

To achieve the study objectives, the following will be performed:

* Visual assessment of the severity of hirsutism on the modified Ferriman-Gallwey scale
* Visual assessment of the severity of androgenetic alopecia on the Ludwig scale.

Eligibility criteria: Inclusion Criteria:

* oligoovulation, i.e. menstrual cycles every \<21 days or \>35 days
* age 18-45 years
* diagnosis of PCOS.

Exclusion Criteria:

* none

Primary outcomes:
measure: Comparison of the severity of hirsutism in the PCOS and HPOD groups
timeFrame: up to 6 months
measure: Comparison of the severity of endogenetic alopecia in the PCOS and HPOD groups
timeFrame: up to 6 months
measure: Calculation of cut-off point for diagnosing hirsutism in the study population
timeFrame: up to 6 months
measure: Assessment of diagnostic convergence of mFG and LS scales in diagnosing clinical hyperandrogenism
timeFrame: up to 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Krakow
country: Poland
facility: Jagiellonian University Medical College
Study officials:
affiliation: Jagiellonian University
name: Kazimierz Pityński, Prof., PhD, MD
role: STUDY_CHAIR
References:
Clinical trial NCT04625998: Texas Childhood Obesity Research Demonstration (TX CORD) Project -Primary Prevention Study
Official title: Systems Approach to Obesity Prevention in Underserved Children in Texas - Primary Prevention
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pediatric Obesity
Keywords: Pediatric obesity
Diet
Physical activity
Schools
Early care and education
Lead sponsor: The University of Texas Health Science Center, Houston
Sponsor class: OTHER
Collaborators: name: Centers for Disease Control and Prevention
name: Baylor College of Medicine
name: Seton Healthcare Family
name: Texas Department of State Health Services
name: Duke University
name: City University of New York, School of Public Health
First posted: 2020-11-12
Enrollment: 4378
Sex: ALL
Minimum age (years): 2
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: A systems approach emphasizes the linkage between individual behavior change strategies and social and physical environmental changes, which act synergistically to facilitate (or inhibit) healthy eating and active living. We hypothesize that among low income, ethnically diverse overweight and obese children, aged 2-12 years, a systems approach to child obesity will reduce BMI compared to primary prevention alone.


Eligibility criteria: Inclusion Criteria:

* Children attending selected elementary schools or Head Start Centers in the catchment areas.
* Ages 2 to 12

Exclusion Criteria:

* Children who are special needs

Primary outcomes:
measure: Change in Population-level Child Obesity as Defined by BMI z-score
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: The University of Texas Health Science Center, Houston
name: Deanna M Hoelscher, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Baylor College of Medicine
name: Nancy F Butte, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Hoelscher DM, Butte NF, Barlow S, Vandewater EA, Sharma SV, Huang T, Finkelstein E, Pont S, Sacher P, Byrd-Williams C, Oluyomi AO, Durand C, Li L, Kelder SH. Incorporating primary and secondary prevention approaches to address childhood obesity prevention and treatment in a low-income, ethnically diverse population: study design and demographic data from the Texas Childhood Obesity Research Demonstration (TX CORD) study. Child Obes. 2015 Feb;11(1):71-91. doi: 10.1089/chi.2014.0084. Epub 2015 Jan 2.
citation: Oluyomi AO, Byars A, Byrd-Williams C, Sharma SV, Durand C, Hoelscher DM, Butte NF, Kelder SH. The utility of Geographical Information Systems (GIS) in systems-oriented obesity intervention projects: the selection of comparable study sites for a quasi-experimental intervention design--TX CORD. Child Obes. 2015 Feb;11(1):58-70. doi: 10.1089/chi.2014.0054. Epub 2015 Jan 14.
Clinical trial NCT03015298: Comparing the Diagnostic Role of PET/MRI and of PET/CT Among Patients With Gastric Cancer
Official title: Comparing the Diagnostic Role of 18F-FDG PET/MRI and of 18F-FDG PET/CT Among Patients With Gastric Cancer：A Randomized Controlled Trial
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Gastric Cancer Stage
Keywords: gastric cancer
Simultaneous PET/MRI
PET/CT
Lead sponsor: Chinese PLA General Hospital
Sponsor class: OTHER
First posted: 2017-01-10
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: The cohort will recruit from patients diagnosed as gastric cancer and treated in the Department of general surgery.

Brief summary: The results of PET/MRI and PET/CT in each recruited gastric cancer patients will be compared.

Detailed description: A prospective comparison of PET/MRI and PET/CT for gastric cancer will be performed,to evaluate the value of PET/MRI in predicting the preoperative staging and resectability of gastric cancer and investigate the role of PET/MRI in gastric cancer diagnosis.The evaluation parameters are the diagnostic accuracy of gastric cancer staging( including the overall accuracy, sensitivity, and specificity) and the receiver operating characteristic (ROC).

Eligibility criteria: Inclusion Criteria:

1. Histological diagnosis of gastric cancer
2. No previous treatment history for gastric cancer
3. Without complications of obstruction,bleeding and so on
4. Without severe diabetes,the levels of blood glucose \<6.2 mmol/L .
5. No cardiac pacemarker,never stimulator or other metal substitute materials in vivo.

Exclusion Criteria:

1. With other neoplastic disease.
2. Suffering acute inflammatory disease
3. History of chemo-radiotherapy
4. Suffering prostate hyperplasia,glaucoma

Primary outcomes:
measure: The results of the PET/MRI and PET/CT examination
timeFrame: 3 days
Secondary outcomes:
measure: Histopathological diagnosis
timeFrame: 5 days
measure: Results of CT/Endoscopic ultrasound(EUS) image
timeFrame: 3 days
measure: Numerical values of Standard uptake value(SUV)
timeFrame: 3 days
measure: Apparent Diffusion Coefficient(ADC)
timeFrame: 3 days
measure: The expression level of Receptor tyrosine-protein kinase erbB-2(HER2)
timeFrame: 5 days
measure: The expression level of Receptors for vascular endothelial growth factor(VEGFR)
timeFrame: 5 days
measure: Follow-up data
timeFrame: at lest 6 months
Other outcomes:
Locations:
Study officials:
affiliation: the Chinese PLA General Hospital
name: Jianxin Cui, Doctor
role: STUDY_DIRECTOR
affiliation: the Chinese PLA General Hospital
name: Yi Liu
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02301598: Femtosecond Laser-assisted Anterior Lamellar Keratoplasty
Official title: Femtosecond Laser-assisted Anterior Lamellar Keratoplasty
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Keratoconus
Corneal Opacity
Keywords: femtosecond laser
anterior lamellar keratoplasty
atomic-force microscopy
Lead sponsor: The S.N. Fyodorov Eye Microsurgery State Institution
Sponsor class: OTHER_GOV
First posted: 2014-11-26
Enrollment: 13
Minimum age (years): 18
Maximum age (years): 52
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of the study is evaluating safety and clinical efficiency of full femtosecond laser-assisted anterior lamellar keratoplasty (FS-ALK) for curing patients with keratoconus and corneal opacities

Detailed description: Keratoplasty is the most widely spread tissue transplantation procedure. Although penetrating keratoplasty (PKP) is still commonly used for curing corneal dystrophy and opacities of different genesis, lamellar techniques provide significant advantages in terms of safety and predictability.

Al in all 13 FS-ALK procedures were performed for 11 eyes with advanced keratoconus and 2 eyes with superficial corneal scattering Before and after surgery uncorrected visual acuity (UCVA), best spectacle-corrected visual acuity (BSCVA), postoperative astigmatism, endothelial cell loss, central cornea thickness, residual recipient's tissue thickness, corneal hysteresis (CH) and corneal resistance factor (CFR) were evaluated . At 1-year follow-up Confoscan investigation of donor-recipient interface was performed.

All FS-ALK procedures were performed with Intralase FS 60kHz femtosecond laser in a following way. At first a 80% thickness corneal graft was prepared. Then maximum thickness recipients corneal dissection was performed according to OCT (optical coherence tomography) data and superficial tissue was removed. Transplant was fixed in a resulted bed by continuous suture.

Eligibility criteria: Inclusion Criteria:

* Advanced keratoconus or stromal corneal scattering
* Normal endothelial cell density

Exclusion Criteria:

* Acute keratoconus in the anamnesis
* Low endothelial cell density
* Age under 18 years

Primary outcomes:
measure: Mean endothelial cell loss
timeFrame: 12 months after surgery
measure: Mean postoperative astigmatism
timeFrame: 12 months after surgery
measure: UCVA (uncorrected visual acuity)
timeFrame: 12 months after surgery
measure: BSCVA (best spectacle-corrected visual acuity)
timeFrame: 12 months after surgery
Secondary outcomes:
measure: Corneal hysteresis
timeFrame: 12 months after surgery
measure: Corneal resistance factor
timeFrame: 12 months after surgery
measure: Central corneal thickness
timeFrame: 12 months after surgery
measure: Residual recipient's tissue thickness
timeFrame: 12 months after surgery
Other outcomes:
Locations:
Study officials:
affiliation: The S.N. Fedorof Federal State Institution
name: Boris Malyugin, MD,PhD,prof.
role: STUDY_DIRECTOR
References:
Clinical trial NCT05730998: Cranberry for the Prevention of Urinary Tract Infections
Official title: The Beneficial Effects of a Cranberry-based Oral Nutritional Supplement on the Prevention of Urinary Tract Infections in Diabetic Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetes
Urinary Infection
Lead sponsor: Azienda di Servizi alla Persona di Pavia
Sponsor class: OTHER
First posted: 2023-02-16
Enrollment: 60
Sex: FEMALE
Minimum age (years): 70
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This research aims to evaluate the potential benefit of an oral nutritional supplement based on Anthocran phytosome compared to placebo on the prevention of urinary infections, including microbiota analyzes, in postmenopausal women (\> 70 years) with diabetes.

For each subject enrolled, all parameters relating to urinary infections will be assessed at the beginning (baseline), every 2 months from the start of treatment and at the end of treatment (6 months), with urine analysis and quality of life questionnaires.


Eligibility criteria: Inclusion Criteria:

* postmenopausal women (\> 70 years) with diabetes.
* treatment with SGLT-2 inhibitors
* disease duration for at least 10 years, with at least 1 episode of infection the previous year and Charlson's co-morbidity index\> 6.

Primary outcomes:
measure: urinalysis
timeFrame: At baseline
measure: urinalysis
timeFrame: After two months of treatment
measure: urinalysis
timeFrame: After four months of treatment
Secondary outcomes:
measure: urine culture
timeFrame: At baseline
measure: urine culture
timeFrame: After two months of treatment
measure: urine culture
timeFrame: After four months of treatment
measure: urine culture
timeFrame: After six months of treatment
Other outcomes:
Locations:
city: Pavia
country: Italy
facility: l'Istituto di Riabilitazione e cura "Santa Margherita" di Pavia, Azienda di Servizi alla Persona (ASP).
Study officials:
References:
Clinical trial NCT03023098: Drug-eluting Balloon vs. Conventional Balloon in the Treatment of (re)Stenosis - a Randomized Prospective Study
Official title: Drug-eluting Balloon vs. Conventional Balloon in the Treatment of (re)Stenosis - a Randomized Prospective Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Peripheral Artery Occlusive Disease
Peripheral Artery Restenosis
Peripheral Artery Stenosis
Keywords: Restenosis
Drug-eluting balloon
Vein graft
Lead sponsor: Helsinki University Central Hospital
Sponsor class: OTHER
First posted: 2017-01-18
Enrollment: 57
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether the use of drug-eluting balloons is effective in the treatment of (re)stenosis in bypass vein grafts.

Detailed description: Drug-eluting devices have proved beneficial in the treatment of stenosis in native coronary and lower limb arteries. Stenosis and restenosis is a known problem in bypass vein grafts, and drug-eluting devices might be beneficial in this field as well.

In the procedure a conventional balloon is passed through the stenosis which is then dilated. After this patients are randomized before a second dilatation with either a conventional balloon or a drug-coated balloon.

The stenosis is evaluated preoperatively and followed up by means of ultrasound by a vascular technician. Follow-up will end at 12 months.

Eligibility criteria: Inclusion Criteria:

* Any venous bypass with stenosis warranting intervention

Exclusion Criteria:

* Previous PTA with drug-eluting balloon, thrombolysis, coagulopathy

Primary outcomes:
measure: TLR (Target lesion revascularization)
timeFrame: 12 months
measure: Graft occlusion
timeFrame: 0-12 months
Secondary outcomes:
measure: Major amputation
timeFrame: 0-12 months
measure: Death
timeFrame: 0-12 months
Other outcomes:
measure: Primary assisted patency
timeFrame: 0-12 months
Locations:
city: Helsinki
country: Finland
facility: Helsinki University Hospital
Study officials:
affiliation: Helsinki University Hospital, Dept. of Vascular Surgery
name: Maarit Venermo, M.D., Ph.D.
role: STUDY_DIRECTOR
References:
citation: Bjorkman P, Kokkonen T, Alback A, Venermo M. Drug-Coated versus Plain Balloon Angioplasty in Bypass Vein Grafts (the DRECOREST I-Study). Ann Vasc Surg. 2019 Feb;55:36-44. doi: 10.1016/j.avsg.2018.04.042. Epub 2018 Aug 6.